Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

The project builds on work at Cambridge to understand the role apelin receptors play in cardiovascular conditions including ischemic heart disease and discover a selective antagonist of the target.

While no financial details were disclosed, BioAge will conduct a phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) along with Lilly’s GLP-1/GIP receptor agonist tirzepatide ...